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See Article, pages 872–878Hepatitis C virus (HCV) is a blood–borne pathogen that chroni-
cally infects approximately 130 million people worldwide and
can lead to liver cirrhosis and hepatocellular carcinoma. HCV is
divided in seven major genotypes, of which genotype 1 causes
the majority of infections in the developed world. In contrast to
several other chronic viral infections, e.g. human immunodeﬁ-
ciency virus (HIV) and hepatitis B virus (HBV), HCV can be erad-
icated in a subset of individuals who clear acute infection and in
patients that achieve a sustained virologic response (SVR) after
treatment. Cure of HCV decreases the risk of end-stage liver dis-
ease and/or hepatocellular carcinoma, even in patients who are
cirrhotic. It is, therefore, generally recommended that chronically
infected individuals undergo treatment if they are expected to
tolerate the current medications. For more than a decade, treat-
ment for all HCV genotypes has been based on a combination
of interferon-a (IFNa) and ribavirin (RBV), with the main vari-
ables being duration of treatment, the formulation of IFNa, and
the dosage of RBV. This combination has empirically proven efﬁ-
cacious but its mechanisms of action remain elusive. IFNa is
believed to have both direct antiviral, as well as host immuno-
stimulatory effects, and a wide array of mechanisms have been
proposed for RBV, from increased viral mutagenesis to helper T
cell modulation [6]. Even with optimal treatment duration, for-
mulation and dosing, however, less than half of genotype 1/4
and approximately two thirds of genotype 2/3 infected patients
achieve SVR [7]. Meanwhile, both drugs result in signiﬁcant
adverse events in the majority of patients, most notably cytope-
nias that frequently require growth factor administration, ﬂu like
symptoms, and neuropsychiatric side effects. It is for these rea-
sons that new drugs are currently under development.
HCV is a positive stranded RNA virus that encodes a single
polyprotein, which is cleaved by host and viral proteases into
its functional structural and non-structural (NS) subunits. Two
of the viral gene products, namely the NS3-4A protease and
NS5B polymerase, have proven attractive drug targets. Over theJournal of Hepatology 20
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irals (DAAs) or STAT-C drugs, have been developed and some
have advanced into promising clinical trials. In combination with
IFNa and RBV, the ﬁrst NS3-4A protease inhibitors showed a 20–
37% higher likelihood of obtaining SVR in genotype 1 patients and
are expected to enter into clinical practice in the coming 1–
2 years [9,11,12]. DAA monotherapy, however, rapidly selects
for drug-resistant HCV genomes, typically within days. Thus,
approval of these drugs is initially expected to be in combination
with IFNa and RBV, allowing only modest gain in tolerability.
Pressing questions include whether IFNa/RBV-free regimens will
be able to achieve SVR in an acceptable percentage of patients,
how many DAAs are required to prevent viral breakthrough,
and how long combination DAA therapy needs to be adminis-
tered in order to achieve SVR.
Because of its restricted tropism for human and chimpanzee
hepatocytes, the only small animal models for HCV are mice that
have been transplanted with human hepatocytes. Immunodeﬁ-
ciency and targeted liver injury are prerequisites for these mice
to accept the human xenograft. The two best-deﬁned models
are based on a urokinase plasminogen activator transgene
expressed under the albumin promoter (alb-uPA mice) and a
fumaryl acetoacytate hydrolase deﬁciency (FAH/ mice). Fol-
lowing transplantation of adult human hepatocytes, ablation of
the mouse liver cells by either the uPA transgene [13,14] or lack
of FAH [1,2] allows repopulation by the human hepatocytes. Over
a typical time period of 2–3 months, these mouse livers show
progressive human chimerism, in some cases >90% [3,16], and
can be monitored by human albumin levels in their serum. Mice
that have achieved high (>10%) human chimerism support infec-
tion and sustained replication of a variety of HCV strains, includ-
ing genotype 1 patient isolates [3,13]. Although these models
have several limitations, most notably the lack of an adaptive
immune system, they are the only small animal models in which
several aspects of the HCV life cycle can be studied in vivo [5].
In this issue of the Journal of Hepatology, Ohara et al. [15]
address several important questions surrounding DAA treatment
using xenotransplanted alb-uPA mice. They investigate the NS3-
4A inhibitor telaprevir (also known as VX-950), which is likely to
be one of the ﬁrst DAAs approved for clinical use, and the NS5B11 vol. 54 j 848–850
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Fig. 1. Utility of human liver chimeric mice in HCV drug development. Abbreviated schematic of (HCV) drug development. Human liver chimeric mice may have a role in
pre-clinical in vivo drug efﬁcacy and DMKP/safety assessments. Results can potentially guide more expensive (pre-)clinical studies in chimpanzees and humans.
DAA = directly acting antiviral, DMKP = drug metabolism pharmaco kinetics pegIFN, pegylated interferon, RBV, ribavirin, SOC, standard of care.
JOURNAL OF HEPATOLOGYinhibitor MK-0608, which is now entering clinical trials. After
determining the IC50 for each drug in culture, and showing that
the combination of telaprevir and MK-0608 is more inhibitory
than either compound alone, they set out to test in vivo efﬁcacy.
Based on previous studies by the same group, higher levels of
telaprevir were used than in clinical trials; for MK-0608, two dif-
ferent doses were administered based on chimpanzee data [4]. As
expected, monotherapy with telaprevir led to a modest (1.1 log)
reduction in viral load, with one out of four animals displaying aJournal of Hepatology 201clinically documented resistance mutation (V36A) two weeks
into monotherapy. MK-0608 was more potent, leading to an aver-
age 2.6 log reduction in HCV titer after four weeks of treatment;
two out of three animals, however, showed viral breakthrough
and a resistance mutation (S282T) previously found in chimpan-
zees. The authors next combined telaprevir with MK-0608, with
or without IFNa. Interestingly, the combination of telaprevir
and low dose MK-0608 was able to clear viremia after four weeks,
although all animals displayed rebound after cessation of treat-1 vol. 54 j 848–850 849
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ment. When IFNa, which is poorly effective as a monotherapy in
this model, was added to the telaprevir/MK-0608 regimen the
results were much more encouraging. All mice became aviremic
at the end of therapy, and 12 weeks after treatment cessation
viral RNA was undetectable in the liver of the one surviving
mouse, supporting the notion that the virus had truly been erad-
icated. Lastly, Ohara et al. administered telaprevir in combination
with a high dose of MK-0608 and showed that this regimen, in
contrast to low dose MK-0608, was able to prevent rebound vire-
mia after treatment cessation. Furthermore, all 5 mice remained
aviremic at 18 weeks post-treatment. This outcome, which could
be considered SVR, provides an encouraging precedent for a com-
bination of two DAAs, albeit at very high doses, resulting in erad-
ication of the virus.
The report by Ohara et al. sheds light on several important
principles in the rapidly developing ﬁeld of DAA treatment, and
may provide cues for future trial design. First, these results pro-
pose that combination therapy may only require two highly
potent DAAs in order to prevent viral resistance. In contrast to
the rapid emergence of resistant virus under DAA monotherapy
or low dose combination therapy, the recently reported results
from a DAA combination trial are in line with these animal data.
INFORM-1 is a phase I trial of a NS3-4A protease inhibitor
(R7227) combined with a nucleoside NS5B polymerase inhibitor
(R7128) without IFNa/RBV for 14 days, followed by IFNa/RBV
therapy up to 48 weeks. After the initial period of combination
therapy, =viremia in 63% of patients fell below 40 IU/ml, and in
25% became undetectable; only one case of viral breakthrough
was observed [8]. The rates of relapse between the groups remain
to be reported. The data of Ohara et al. show that effective inhi-
bition of HCV replication for only a short time can result in viral
clearance without IFNa administration. The exact duration
required to achieve SVR will likely depend on the potency of
the DAA regimen. If these ﬁndings can be extrapolated to
patients, it may warrant future trials of combination DAA treat-
ment without IFNa/RBV consolidation. Lastly, Ohara et al. dem-
onstrate that SVR may be achieved without RBV. This is
especially relevant since two recent reports indicated higher
relapse rates in patients that received low dose RBV, both with
regular IFNa/RBV as well as in the SPRINT1 protease inhibitor
trial [10,11]. None of their telaprevir and high dose MK-0608
treated mice relapsed, suggesting that RBV will not have to
remain an essential component indeﬁnitely.
The current study by Ohara et al. nicely illustrates the feasibil-
ity of DAA treatment in a small animal model of HCV. Even with a
limited number of animals, many of their ﬁndings are in line with
observations made in chimpanzees and in patients, showing that
small animal models for HCV can be useful in pre-clinical appli-
cations (Fig. 1). Given the likely introduction of many DAAs into
clinical practice over the coming decade, deﬁning optimal treat-
ment regimens will rapidly become very complex. Affordable
small animal models will allow for testing different DAA combi-
nations, duration, and dosing and will hopefully provide clues
how to best cure HCV infected patients without IFNa or RBV.Financial support
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